-- Inaugural Brand From the “new” Tilray
Provides a Broader Spectrum of Formats and Cannabinoid Ratios at a
Better Price Point --
Tilray, Inc. (“Tilray”) (NASDAQ | TSX: TLRY), a leading global
cannabis-lifestyle and consumer packaged goods company, today
announced the launch of Symbios, a complement to the Company’s
existing medical brand portfolio in Canada. This new brand was
developed to provide a broader spectrum of formats and unique
cannabinoid ratios at a better price point while offering medical
patients a full comprehensive assortment of products, including
flower, oils, and pre-rolls for their health and wellness
regiment.
Irwin D. Simon, Tilray’s Chief Executive Officer, said, “Medical
cannabis innovation and patient care are core to the new Tilray’s
business and global growth strategy. As we look ahead, we remain
focused on building momentum across our three medical brands –
Symbios, Aphria, and Tilray -- while meeting the large and growing
demand for new, high-quality cannabis products that promote health,
wellness, and wellbeing.”
Contemporaneous with today’s announcement, Tilray also announced
new high-potency, medical cannabis topicals under the Aphria brand
designed to target inflammatory joint disease by regulating tissue
inflammation when applied topically to the skin1. They are made
from a vegan and cruelty-free cream formulation and include CBD 750
(containing 750mg of CBD) and Balance 750 (containing 375mg of THC
and 375mg of CBD).
Jim Meiers, President, Tilray Canada, added, “Symbios and our
new Aphria topical treatments are exciting new additions to our
medical portfolio in Canada, providing our patients with a broader
selection of unique product formats to meet their needs and
preferences. Our industry is only in the early stages of creating
and bringing to market cannabinoid medicine options that meet
patient needs. We are committed to building our leadership position
in Canada now and into the future.”
Symbios and Aphria’s new high-potency topicals join a range of
other products, including cannabis oils, soft gels, oral sprays,
whole dried flower, and vapes that are now available to all medical
patients through the Aphria online medical patient portal.
For more information about Symbios and Aphria medical cannabis
products, visit: www.Aphria.ca
About Aphria, Tilray’s Medical Cannabis Brand
Aphria started in 2014 in Leamington, Ontario, as one of the
first companies to provide access to legal, medical cannabis. Since
then, the Aphria brand has grown to be one of the top medical
cannabis providers globally, with operations in Canada and
international markets. Aphria remains committed to supplying its
growing patient base with safe, affordable, consistent, and
effective medical cannabis products.
About Tilray
Tilray, Inc. is a leading global cannabis-lifestyle and consumer
packaged goods company with operations in Canada, the United
States, Europe, Australia, and Latin America that is changing
people’s lives for the better – one person at a time – by inspiring
and empowering the worldwide community to live their very best life
by providing them with products that meet the needs of their mind,
body, and soul and invoke a sense of wellbeing. Tilray’s mission is
to be the trusted partner for its patients and consumers by
providing them with a cultivated experience and health and
wellbeing through high-quality, differentiated brands and
innovative products. A pioneer in cannabis research, cultivation,
and distribution, Tilray’s unprecedented production platform
supports over 20 brands in over 20 countries, including
comprehensive cannabis offerings, hemp-based foods, and alcoholic
beverages.
For more information about Tilray, Inc., visit:
www.Tilray.com
Forward-Looking Statements
Certain statements in this communication that are not historical
facts constitute forward-looking information or forward-looking
statements (together, “forward-looking statements”) under Canadian
securities laws and within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, that are intended to
be subject to the “safe harbor” created by those sections and other
applicable laws. Forward-looking statements can be identified by
words such as “forecast,” “future,” “should,” “could,” “enable,”
“potential,” “contemplate,” “believe,” “anticipate,” “estimate,”
“plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and
the negative of these terms or similar expressions, although not
all forward-looking statements contain these identifying words.
Certain material factors, estimates, goals, projections or
assumptions were used in drawing the conclusions contained in the
forward-looking statements throughout this communication. Many
factors could cause actual results, performance or achievement to
be materially different from any forward-looking statements, and
other risks and uncertainties not presently known to the Company or
that the Company deems immaterial could also cause actual results
or events to differ materially from those expressed in the
forward-looking statements contained herein. For a more detailed
discussion of these risks and other factors, see the most recently
filed annual information form of Aphria and the Annual Report on
Form 10-K (and other periodic reports filed with the SEC) of Tilray
made with applicable securities regulatory authorities and
available on SEDAR and EDGAR. The forward-looking statements
included in this communication are made as of the date of this
communication and the Company does not undertake any obligation to
publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by
applicable securities laws.
1 Philpott, Holly T., et al. “Attenuation of early phase
inflammation by cannabidiol prevents pain and nerve damage in rat
osteoarthritis.” Pain. 2017 Dec; 158(12). DOI:
10.1097/j.pain.0000000000001052
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210608005394/en/
For media inquiries, please contact: Berrin Noorata
news@tilray.com
For investor inquiries, please contact: Raphael Gross
203-682-8253 Raphael.Gross@icrinc.com
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Sep 2023 to Sep 2024